StockUS listing USRVTYNYSEHealthcareBalanced

Revvity Inc.(RVTY) Stock Analysis | Healthcare

USD --+0.00%
Reward41Moderate
Risk43Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NYSE
Market cap 17.20Bn
Reward Ratingⓘ41 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ43 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RVTY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Revvity Inc.?

provides health sciences solutions, technologies, and services.

AI Brief Pro

The brief on Revvity Inc.

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Revvity Inc.?

provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 17.20B, and a P/E ratio of 73.8x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Adequate profitability with some margin variability in recent periods.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (41)

Similar stocks to compare

A short list of Diagnostics & Research names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDiagnostics & Research
P/E Ratio73.7703
Beta1.064
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.